Literature DB >> 11136236

Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.

T Igarashi1, C R Brown, Y Endo, A Buckler-White, R Plishka, N Bischofberger, V Hirsch, M A Martin.   

Abstract

The highly pathogenic simian immunodeficiency virus/HIV type 1 (SHIV) chimeric virus SHIV(DH12R) induces a systemic depletion of CD4(+) T lymphocytes in rhesus monkeys during the initial 3-4 weeks of infection. Nonetheless, high levels of viral RNA production continue unabated for an additional 2-5 months. In situ hybridization and immunohistochemical analyses revealed that tissue macrophage in the lymph nodes, spleen, gastrointestinal tract, liver, and kidney sustain high plasma virus loads in the absence of CD4(+) T cells. Quantitative confocal immunofluorescence analysis indicated that greater than 95% of the virus-producing cells in these tissues are macrophage and less than 2% are T lymphocytes. Interestingly, the administration of a potent reverse transcriptase inhibitor blocked virus production during the early T cell phase but not during the later macrophage phase of the SHIV(DH12R) infection. When interpreted in the context of HIV-1 infections, these results implicate tissue macrophage as an important reservoir of virus in vivo. They become infected during the acute infection, gradually increase in number over time, and can be a major contributor to total body virus burden during the symptomatic phase of the human infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136236      PMCID: PMC14644          DOI: 10.1073/pnas.98.2.658

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy.

Authors:  V Natarajan; M Bosche; J A Metcalf; D J Ward; H C Lane; J A Kovacs
Journal:  Lancet       Date:  1999-01-09       Impact factor: 79.321

2.  Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.

Authors:  C C Tsai; P Emau; K E Follis; T W Beck; R E Benveniste; N Bischofberger; J D Lifson; W R Morton
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques.

Authors:  S V Joag; Z Li; L Foresman; E B Stephens; L J Zhao; I Adany; D M Pinson; H M McClure; O Narayan
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Authors:  L Zhang; B Ramratnam; K Tenner-Racz; Y He; M Vesanen; S Lewin; A Talal; P Racz; A S Perelson; B T Korber; M Markowitz; D D Ho
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

5.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Authors:  M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

6.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

7.  Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

Authors:  C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

8.  In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages.

Authors:  C F Perno; S Aquaro; B Rosenwirth; E Balestra; P Peichl; A Billich; N Villani; R Caliò
Journal:  J Leukoc Biol       Date:  1994-09       Impact factor: 4.962

9.  Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication.

Authors:  V M Hirsch; G Dapolito; P R Johnson; W R Elkins; W T London; R J Montali; S Goldstein; C Brown
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

Authors:  K A Reimann; J T Li; R Veazey; M Halloran; I W Park; G B Karlsson; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  182 in total

Review 1.  Surrogacy in antiviral drug development.

Authors:  Sunil Shaunak; Donald S Davies
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

2.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

3.  Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.

Authors:  Magdalena Magierowska; Flavien Bernardin; Seema Garg; Silvija Staprans; Michael D Miller; Koen K A Van Rompay; Eric L Delwart
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 4.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

5.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 6.  Interactions between HIV-1 and mucosal cells in the female reproductive tract.

Authors:  Ruizhong Shen; Holly E Richter; Phillip D Smith
Journal:  Am J Reprod Immunol       Date:  2014-04-01       Impact factor: 3.886

7.  Proliferating cellular nuclear antigen expression as a marker of perivascular macrophages in simian immunodeficiency virus encephalitis.

Authors:  Kenneth Williams; Annette Schwartz; Sarah Corey; Marlene Orandle; William Kennedy; Brendon Thompson; Xavier Alvarez; Charlie Brown; Suzanne Gartner; Andrew Lackner
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Critical Role for Monocytes/Macrophages in Rapid Progression to AIDS in Pediatric Simian Immunodeficiency Virus-Infected Rhesus Macaques.

Authors:  Chie Sugimoto; Kristen M Merino; Atsuhiko Hasegawa; Xiaolei Wang; Xavier A Alvarez; Hiroshi Wakao; Kazuyasu Mori; Woong-Ki Kim; Ronald S Veazey; Elizabeth S Didier; Marcelo J Kuroda
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

9.  Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance.

Authors:  Malavika S Giri; Michael Nebozyhn; Andrea Raymond; Bethsebah Gekonge; Aidan Hancock; Shenoa Creer; Calen Nicols; Malik Yousef; Andrea S Foulkes; Karam Mounzer; Jane Shull; Guido Silvestri; Jay Kostman; Ronald G Collman; Louise Showe; Luis J Montaner
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

10.  Association of platelet-derived growth factor-B chain with simian human immunodeficiency virus encephalitis.

Authors:  Raghava Potula; Navneet Dhillion; Yongjun Sui; Christopher A Zien; Keiko Funa; David Pinson; Matthew S Mayo; Dinesh K Singh; Opendra Narayan; Shilpa Buch
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.